Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors combination therapy versus monotherapy and major adverse cardiovascular events: Do the benefits add up?
Paschalis Karakasis, Dimitrios Patoulias, Nikolaos Fragakis, M. Rosa Bernal‐López, Ricardo Gómez‐Huelgas
Topics & Concepts
MedicineAdverse effectPharmacologyGlucagon-like peptide-1Combination therapyGlucagon-like peptide 1 receptorInternal medicineEndocrinologyReceptorDiabetes mellitusType 2 diabetesAgonistDiabetes Treatment and ManagementMetabolism, Diabetes, and CancerNeuroendocrine Tumor Research Advances